• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Clin Cancer Res. Author manuscript; available in PMC May 1, 2011.
Published in final edited form as:
PMCID: PMC2862089
NIHMSID: NIHMS182856

Crosstalk between Insulin/IGF-1 and GPCR Signaling Systems: A Novel Target for the Anti-diabetic Drug Metformin in Pancreatic Cancer#

Abstract

Insulin/insulin-like growth factor 1(IGF-1) receptors and G protein-coupled receptors (GPCR) signaling systems are implicated in autocrine/paracrine stimulation of a variety of malignancies, including ductal adenocarcinoma of the pancreas, one of the most lethal human diseases. Novel targets for pancreatic cancer therapy are urgently needed. We identified a crosstalk between insulin/IGF-1 receptors and GPCR signaling systems in pancreatic cancer cells, leading to enhanced signaling, DNA synthesis and proliferation. Crosstalk between these signaling systems depends on mTOR complex 1 (mTORC1). Metformin, the most widely used drug in the treatment of type-2 diabetes, activates AMP kinase (AMPK), which negatively regulates mTORC1. Recent results show that metformin-induced activation of AMPK disrupts crosstalk between insulin/IGF-1 receptor and GPCR signaling in pancreatic cancer cells and inhibits the growth of these cells in xenograft models. Given that insulin/IGF-1 and GPCRs are implicated in other malignancies, a similar crosstalk mechanism may be operative in other cancer cell types. Recent epidemiological studies linked administration of metformin with a reduced risk of pancreatic, breast and prostate cancer in diabetic patients. We posit that crosstalk between insulin/IGF-1 receptor and GPCR signaling is a mechanism for promoting the development of certain types of cancer and a target for the prevention and therapy of these diseases via metformin administration.

BACKGROUND

Crosstalk between the insulin/IGF-1 receptor and GPCR signaling systems in pancreatic cancer cells

The major challenge facing cancer research is to identify novel molecules and develop strategies for the treatment of common solid tumors, including ductal adenocarcinoma of the pancreas, a devastating disease with overall 5-year survival rate of only 3–5%. Thus far, a range of targeted therapies against EGFR, RAS/MEK and VEGF have failed to improve survival significantly in clinical trials. Novel targets for therapeutic intervention are urgently needed and will most likely arise from a more detailed understanding of the signaling pathways that stimulate the unrestrained proliferation and invasiveness of these cancer cells.

Signaling pathways do not act in isolation, but crosstalk (i.e. interact) with each other, forming complex signaling networks (1). Multiple lines of evidence support the notion that crosstalk between the insulin/IGF-1 receptor and heptahelical G protein-coupled receptor (GPCR) signaling systemsplays a critical role in the regulation of multiple physiologicalfunctions and in a variety of abnormalprocesses, including cardiovascular and renal pathologies in obesity, metabolic syndrome and type II diabetes [see (2) for refs.]. In turn, epidemiological studies linked long standing type-2 diabetes, obesity and metabolic syndrome with increased risk for developing cancer, including pancreatic and colon cancer (discussed below). At the cellular level, insulin dramatically synergizes with GPCR agonists in inducing mitogenic signaling (3) and many GPCRs and their cognate agonists are implicated as autocrine/paracrine growth factors for multiple solid tumors, including pancreas, colon, prostate and breast (1, 4). The purpose of this article is to discuss recent advances in identifying crosstalk between insulin/IGF-1 receptor and GPCR signaling pathways as a mechanism for enhancing pancreatic cancer cell proliferation and a target for the antidiabetic agent metformin, a potential new tool in the prevention and/or therapy of this disease.

GPCR Signaling

Human pancreatic adenocarcinoma cells express multiple GPCRs that mediate rapid signaling and cell proliferation in response to their corresponding agonists (2, 58) and expression of angiotensin (ANG II) and neurotensin GPCRs is markedly increased in pancreatic cancer tissues (912). Neurotensin acts as a potent growth factor for pancreatic cancer cells (5, 7, 8, 13) and a broad-spectrum GPCR antagonist inhibited the growth of pancreatic cancer cells either in vitro or xenografted into nu/nu mice (14). Transgenic expression of the gastrin GPCR in murine pancreas induced neoplastic proliferation and acinar-ductal transdifferentiation (15).

Heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins), composed of α, β and γ subunits, transduce external signals from heptahelical receptors to intracellular effectors. G proteins are classified according to their α subunits into four subfamilies: Gs, Gi, Gq, and G12. Agonist binding to GPCRs induces movement of the transmembrane-spanning segments and promotes a conformational change in the cytoplasmic domain of the receptor that leads to the exchange of GDP bound to the α subunit of the G protein for GTP. The resulting GTP-Gα and Gβγ subunits stimulate effectors that transduce GPCR activation into multiple downstream signaling responses. These include a rapid increase in the activity of phospholipases C (PLC), D, and A2 leading to the synthesis of lipid-derived second messengers, Ca2+ fluxes, elevation of cAMP and subsequent activation of serine and tyrosine protein phosphorylation cascades, including PKC/PKD, Raf/MEK/ERK, mTOR/p70S6K and Src/FAK. GPCR signaling leading to mitogenesis has been recently reviewed elsewhere (1) and here we focus on studies particularly relevant to pancreatic cancer cells. Some of the major pathways demonstrated in these cells are shown in Fig. 1. Specifically, GPCR-induced Gαq/PLC activation stimulates the hydrolysis of phosphatidylinositol 4, 5-bisphosphate (PIP2) to produce two second messengers: inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG). IP3 triggers the release of Ca2+ from internal stores, leading to a rapid and transient increase in intracellular Ca2+ concentration. DAG remains in the plane of the membrane and directly activates protein kinase C (PKC), a phospholipid-dependent protein kinase family. PKCs induce rapid phosphorylation of cytosolic and membrane-bound proteins, including the downstream protein kinases of the protein kinase D (PKD) family (16). PKD induces MEK/ERK/p90RSK pathway activation and thereby mediates cell proliferation in some cell types (17, 18). PKD is activated in pancreatic cancer cells by GPCR agonists, including neurotensin (6, 19), it is overexpressed in pancreatic cancer tissues (20) and its overexpression promotes pancreatic cancer cell proliferation (21). The PKD family is emerging as an important downstream elements in GPCR-induced mitogenic signaling in pancreatic cancer.

Figure 1
Signal transduction pathways and crosstalk activated by insulin/IGF-1 receptor and GPCR systems. The binding of an agonist to its cognate GPCR induces Gq/PLC activation, hydrolysis of PIP2, generation of Ins(1,4,5)P3 and Ca2+ mobilization as described ...

GPCR agonists also stimulate mTOR (mammalian Target Of Rapamycin)-dependent pathways in many model systems, including pancreatic cancer cells, but the molecular pathways remain incompletely understood (1). mTORC1 is likely to be activated in response to GPCR agonists through the ERK/RSK pathway rather than via phosphatidylinositol 3-kinase (PI3K)/Akt, which is activated weakly by GPCR agonists in pancreatic cancer cells (22). As further developed below, mTORC1 activation is a site of signal convergence and dissemination in the crosstalk between GPCRs and insulin/IGF receptor systems.

Insulin/IGF-1 receptor signaling and pancreatic cancer

Cellular responses to insulin have been extensively characterized in diverse tissues, including liver, muscle, and fat (23, 24), but the signaling pathways activated by insulin/IGF-1 receptors in pancreatic cancer cells are less completely understood. In most cell types, binding of insulin to its tetrameric receptor results in receptor autophosphorylation and activation of the receptor tyrosine kinase, followed by tyrosine phosphorylation of insulin receptor substrates (IRS 1–4) which further propagate downstream signals via assembly of signaling complexes, notably with the p85 regulatory subunit of PI3K (25, 26). The highly related IGF-1 receptor (IGF-1R) can also be activated by insulin (26), in particular at the high concentrations of this hormone present in the pancreatic microenvironment. Furthermore, IGF-1 produced by pancreatic stromal cells in response to factors released by the cancer cells, including hedgehog, can also interact with insulin/IGF-1 receptors in these cells (27). Accordingly, pancreatic cancer cells express insulin and IGF-1 receptors and overexpress IRS-1 and IRS-2 (28, 29), underscoring the importance of these pathways in promoting pancreatic cancer proliferation.

A key insulin/IGF-1R-induced pathway via IRS in most cell types is the PI3K/Akt/mTORC1 signaling module (26). This pathway plays a pivotal role in the proliferation and survival of pancreatic cancer cells (30) and is activated in pancreatic cancer tissues (31). Products generated by PI3K activate 3-phosphoinositide-dependent kinase (PDK1), which in turn phosphorylates and activates Akt. Interestingly, the Akt2 gene is amplified or activated in a subset of pancreatic carcinomas. In contrast, activating mutations in upstream elements of the PI3K pathway (either in PIK3CA or PTEN) have not been detected in pancreatic cancer (32). It is conceivable that stimulation of PI3K by intrapancreatic insulin/IGF-1 in combination with activated KRAS (see below) is sufficient to stimulate potently the PI3K pathway and remove evolutionary selection for mutations in PIK3CA or PTEN (33).

An important downstream target of the PI3K/AKT pathway is mTOR, which integrates and transmits signals from a diverse array of signaling pathways to regulate cell survival and growth through changes in mRNA translation, ribosomal biogenesis, autophagy and metabolism (34, 35). mTOR functions as a catalytic subunit in two distinct multiprotein complexes, mTORC1 and mTORC2 (34). mTORC1, a complex of mTOR, the substrate binding subunit raptor, GβL, and PRAS40, is responsible for the phosphorylation and regulation of at least two regulators of protein synthesis, the 40S ribosomal protein subunit S6 kinase (S6K) and the inhibitor of protein synthesis 4E-binding protein 1, referred as 4EBP1 (25, 36). mTORC1 is potently inhibited by rapamycin whereas mTORC2, which consists of mTOR, rictor, GβL and Sin1, is not inhibited by short-term treatment with this agent (35, 37).

There have been important advances in understanding the regulation of mTORC1 signaling. The heterodimer of TSC2 (tuberin) and TSC1 (hamartin) represses mTOR activity by acting as the GTPase-activator protein for the small G protein Rheb (Ras homolog enriched in brain), a potent activator of mTORC1 when present in a GTP-bound state (38, 39). Phosphorylation ofTSC2 by Akt on Ser939 and Thr1462 (or by ERK/p90RSK on Ser664 and Ser1798), suppresses its GTPase activity towards Rheb leading to Rheb-GTP and thereby to mTORC1 activation. In addition, Rheb-GTP stimulates phospholipase D1 (PLD1) to generate phosphatidic acid, a positive effector of mTORC1 activation (40) and an alternative route to DAG generation (1). Recent evidence obtained with pancreatic cancer cells suggests that mTORC1 has an hitherto unrecognized function in cellular regulation, namely mediation of crosstalk with other signal transduction pathways leading to heightened cellular responsiveness to GPCR agonists (2, 8).

Insulin/IGF-1 and GPCR signaling pathways crosstalk through mTORC1

Although the signaling pathways activated by either GPCR agonists or insulin/IGF-1 have been the subject of intense scrutiny (1, 23, 24, 41), much less is known about the mechanisms by which these pathways crosstalk in pancreatic cancer cells or in any other cell type. Crosstalk between different signaling pathways occurs at the most proximal level (i.e. receptor to receptor) as well as at a variety of loci further downstream in signaling cascades.

Recently, we identified a novel crosstalk between insulin/IGF-1 receptors and GPCR signaling systems in pancreatic cancer cells (2, 8). Exposure of these cells to physiological concentrations of insulin rapidly augmented early signals, including intracellular Ca2+ mobilization, in response to multiple agonists of Gq-coupled receptors (2, 8). Insulin-induced potentiation of GPCR signaling was prevented by inhibitors of PI3K or by the specific mTORC1 inhibitor rapamycin. These results indicate that the PI3K/Akt/mTORC1 pathway mediates a novel crosstalk between insulin receptor and GPCR signaling systems (2). In turn, GPCRs induce mTORC1 activation via ERK/p90RSK rather than PI3K/Akt, implying that mTORC1 is a point of convergence and amplification in the signaling network induced by insulin/IGF-1 and GPCR agonists.

Further results show that insulin/IGF-1 also crosstalks with GPCR agonists to promote long-term biological responses in pancreatic cancer cells, including DNA synthesis, proliferation and anchorage-independent growth (8). We hypothesize that the concomitant activation of the PI3K/Akt pathway (via insulin/IGF-1 receptor), the Gq/PLC/PKD/ERK pathway (via agonist-induced Gq signaling and enhanced by insulin/IGF-1 signaling) and mTORC1 (synergistically by insulin/IGF-1-induced PI3K/Akt and GPCR-stimulated ERK/p90RSK) in pancreatic cancer cells potently stimulates DNA synthesis and proliferation of these cancer cells. In addition, Akt and ERK phosphorylate other targets implicated in pancreatic cell survival and expression of cell cycle genes. Since both the ERK and PI3K pathways are well known effectors of KRAS (42), the activating mutation of KRAS (apparent in 90% of pancreatic cancers) is likely to reinforce the crosstalk between insulin/IGF-1 receptor and GPCR signaling systems, thereby increasing the robustness of the network induced by insulin/IGF-1 and GPCR agonists in pancreatic cancer cells. Thus, crosstalk between these signaling pathways operates at multiple levels and stimulates anchorage-dependent and anchorage-independent proliferation of pancreatic cancer cells.

CLINICAL-TRANSLATIONAL ADVANCES

Metformin disrupts crosstalk between insulin/IGF-1 and GPCR signaling

The biguanide metformin (1,1-dimethylbiguanide hydrochloride, Fig. 1) is the most widely prescribed drug for treatment of type 2 diabetes in the world. Although it has been in clinical use for decades, its precise molecular mechanism of action remains incompletely understood. The primary systemic effect of metformin is the lowering of blood glucose levels through reduced hepatic gluconeogenesis and increased glucose uptake in peripheral tissues, including skeletal muscles and adipose tissue (43). Metformin not only lowers blood glucose but also reduces the hyperinsulinemia associated with insulin resistance.

At the cellular level, metformin is known to stimulate AMP activated protein kinase (AMPK) activation (44). AMPK is a conserved regulator of the cellular response to low energy, and it is activated when ATP concentrations decrease and 5′-AMP concentrations increase in response to nutrient deprivation, hypoxia or metformin administration (45). AMPK exists as a heterotrimer, composed of the catalytic kinase α subunit and two associated regulatory subunits,β and γ (45). AMP directly binds to the AMPK γ subunit, causing a conformational change that exposes the critical threonine (Thr172 in humanAMPK) in the activation loop of the α subunit. The ubiquitously expressed and evolutionarily conserved serine/threonine kinase LKB-1/STK11 (Liver kinase B1/serine threonine kinase 11) represents the major (but not the only) kinase phosphorylating the AMPK activation loop under conditions of energy stress (46). LKB-1/STK11 is mutated in the Peutz-Jegher syndrome (45), characterized by predisposition to gastrointestinal neoplasms, including pancreatic adenocarcinoma.

In contrast to rapamycin, AMPK inhibits mTORC1 at multiple levels: 1) AMPK stimulates TSC2 function via phosphorylation on Ser1345 (4749), leading to accumulation of Rheb-GDP (the inactive form) and thereby to inhibition of mTORC1 activation; 2) AMPK also inhibits mTORC1 signaling by direct phosphorylation of raptor (on Ser722 and Ser792), which disrupts its association with mTOR (50).

Since our studies identified mTORC1 as a site of signaling crosstalk, we examined whether metformin-induced AMPK activation opposes interaction between insulin/IGF-1 receptor and GPCR signaling pathways in pancreatic cancer cells. We found that metformin prevented crosstalk between insulin/IGF-1 receptor and GPCR signaling systems on Ca2+ mobilization, mTORC1 activation, DNA synthesis and proliferation in a variety of pancreatic cancer cell lines [see (8) for details]. We concluded that metformin disrupts crosstalk between insulin/IGF-1 and GPCR signaling systems through AMPK in human pancreatic cancer cells.

Further studies demonstrated that metformin administration markedly inhibited the growth of human pancreatic cancer cells xenografted in nu/nu mice (8). In addition, metformin prevented carcinogen-induced pancreatic acinar cancer in hamsters maintained in high-fat diets (51) and inhibited the proliferation of breast and p53-/- colon cancer cells in preclinical models (5254). A recent study suggested that breast cancer stem cells, with activated mTORC1 pathway, were selectively targeted by metformin in vitro and in a xenograft mouse model (55). All these studies suggest that the antiadiabetic drug metformin provides a novel therapy for pancreatic cancer and other insulin-related tumors, including those from colon and breast.

Type 2 diabetes mellitus is associated with pancreatic cancer and metformin administration reduces the risk of cancer

A large number of epidemiological studies linked long standing type-2 diabetes, obesity and metabolic syndrome with increased risk for developing a variety of clinically aggressive cancers, including pancreatic and colon cancer (56). These metabolic conditions are characterized by peripheral insulin resistance, compensatory overproduction of insulin by the β cells of the islet, and increased bioavailability of IGF-1. Given the complexity of the pancreatic portal microcirculation (57) and the close topographical relationship between the islets and small ducts, it is conceivable that locally overproduced insulin acts directly on insulin/IGF-1 receptors expressed by ductal cells with KRAS mutation, stimulating crosstalk with GPCRs also expressed by these cells.

Remarkably, recent epidemiological reports linked administration of metformin with a reduced risk of cancer in diabetic patients [reviewed in (58)]. For example, an observational cohort study involving patients with type 2 diabetes mellitus who were new users of metformin showed a 37% adjusted reduced risk of cancer as compared with diabetics, who had never used metformin (59). Other studies observed a lower cancer-related mortality rate in patients with type 2 diabetes who received metformin as compared with other treatments, including exogenous insulin or sulfonylureas (58). Strikingly, a recent study showed that diabetic patients who had taken metformin had a 62% lower adjusted incidence of pancreatic cancer compared with those who had not taken metformin (60). In contrast, diabetic patients who had taken insulin or insulin secretagogues (e.g. sulfonylureas) had a significantly higher risk of pancreatic cancer compared with diabetic patients who had not taken these drugs (60). Although epidemiological associations do not establish causation, these studies linked administration of metformin with a reduced incidence and improved prognosis in cancer patients, including pancreatic cancer.

Cinical Trials

There are many interventional clinical trials (completed, active or in recruiting phase) testing the efficacy of metformin, either alone or in combination with other drugs, in patients with type 2 diabetes mellitus and other conditions, including insulin resistance, hyperinsulinemia, obesity, polycystic ovary syndrome (PCOS), atherosclerosis, hypertension, dyslipidemias and nonalcoholic steatohepatitis (NASH). These trials (see ClinicalTrials.gov for details) offer a wealth of information regarding the safety and tolerability of metformin in healthy subjects or in patients with type 2 diabetes mellitus and other conditions. In view of the evidence obtained with cells in culture and preclinical animal models as well as the epidemiological studies linking metformin administration with reduced risk of cancer in diabetic patients, a number of interventional clinical trials are being developed in different countries to test the effects of metformin in human cancers. Most of them are in the recruiting phase. Three independent studies in the US (sponsored by the M.D. Anderson Cancer Center, the University of Columbia and the Vanderbilt-Ingram Cancer Center in collaboration with the NCI), another sponsored by Mount Sinai Hospital, Canada, and a phase II study, sponsored by the Seoul National University Hospital, will be testing metformin in patients with breast cancer who are about to undergo surgery to determine cell proliferation rates and signaling biomarkers in tumour tissue. A phase II study, sponsored by the University Health Network, Toronto, is recruiting participants for investigating the effect of metformin therapy on the proliferation of prostate cancer cells prior to radical prostatectomy. A phase I trial, sponsored by the London Regional Cancer Program at London Health Sciences Centre, will examine side effects and best dose of metformin when given together with temsirolimus (a rapamycin analogue) in treating patients with metastatic or unresectable solid tumors or lymphoma.

Despite its enormous clinical implications, it should be emphasized that there is no complete understanding of the precise molecular mechanism by which metformin inhibits the proliferation of cancer cells. Further research is required to clarify the extent to which relevant doses of metformin act to inhibit the respiratory chain, stimulate AMPK in cancer cells and elucidate the contribution of AMPK-dependent pathways, including inhibition of crosstalk signaling, to its antineoplastic effects. These topics require further investigation before large-scale (phase III-IV) clinical trials can be initiated.

Conclusions

The current paradigm of pancreatic cancer development is that activated KRAS serves to initiate precursor lesions, including pancreatic intraepithelial neoplasias (PanIN). Subsequent progressive accumulation of pro-oncogenic mutations during the promotional phase of pancreatic tumorigenesis requires sustained cell proliferation. We propose that the crosstalk between insulin/IGF-1 and GPCR signaling pathways, reinforced by KRAS activation, plays a role in the promotional phase of these initiated cells and provides a novel target for therapeutic intervention. Since insulin/IGF-1 and GPCR signaling are implicated in autocrine/paracrine stimulation of other malignancies, a similar crosstalk mechanism may be operative in the promotional phase of other cancer cell types.

Because metformin-induced activation of AMPK inhibits mTORC1 function at multiple levels, it is plausible that metformin inhibits pancreatic cancer growth via AMPK-mediated inhibition of mTORC1 activation (Fig. 1). Given that insulin/IGF-1 appears to play a critical role in pancreatic cancer development and that GPCRs are implicated as autocrine/paracrine signals in this process, it is of interest that metformin disrupted crosstalk between insulin/IGF-1 and GPCR signaling pathways. We posit that sites of positive crosstalk between signaling pathways activated in cancer cells are critical targets for cancer therapy.

Food and Drug Administration (FDA)-approved drugs have usually favorable pharmacological properties and safety profiles. Unexpected biological activities of such well-characterized inhibitors therefore represent particularly exciting possibilities for rapid translational research. Given the growth-inhibitory effects of metformin on pancreatic cancer cells in vitro and in vivo, we hypothesize that this agent, widely used in type 2 diabetes, can offer a novel approach for the prevention and treatment of pancreatic cancer and other solid malignancies.

Footnotes

#Work in the laboratory of ER is supported by NIH Grants R21CA137292, R01 DK56930, R01 DK55003 and P30 DK41301.

References

1. Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J Cell Physiol. 2007;213:589–602. [PubMed]
2. Kisfalvi K, Rey O, Young SH, Sinnett-Smith J, Rozengurt E. Insulin Potentiates Ca2+ Signaling and Phosphatidylinositol 4,5-Bisphosphate Hydrolysis Induced by Gq Protein-Coupled Receptor Agonists through an mTOR-Dependent Pathway. Endocrinology. 2007;148:3246–57. [PubMed]
3. Rozengurt E. Early signals in the mitogenic response. Science. 1986;234:161–6. [PubMed]
4. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94. [PubMed]
5. Ryder NM, Guha S, Hines OJ, Reber HA, Rozengurt E. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: Neurotensin responsiveness and mitogenic stimulation. J Cell Physiol. 2001;186:53–64. [PubMed]
6. Guha S, Rey O, Rozengurt E. Neurotensin Induces Protein Kinase C-dependent Protein Kinase D Activation and DNA Synthesis in Human Pancreatic Carcinoma Cell Line PANC-1. Cancer Res. 2002;62:1632–1640. [PubMed]
7. Guha S, Lunn JA, Santiskulvong C, Rozengurt E. Neurotensin Stimulates Protein Kinase C-dependent Mitogenic Signaling in Human Pancreatic Carcinoma Cell Line PANC-1. Cancer Res. 2003;63:2379–2387. [PubMed]
8. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009;69:6539–45. [PMC free article] [PubMed]
9. Elek J, Pinzon W, Park KH, Narayanan R. Relevant genomics of neurotensin receptor in cancer. Anticancer Res. 2000;20:53–8. [PubMed]
10. Wang L, Friess H, Zhu Z, et al. Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clinical Cancer Res. 2000;6:566–71. [PubMed]
11. Reubi JC, Waser B, Friess H, Beuchler M, Laissue J. Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut. 1998;42:546–50. [PMC free article] [PubMed]
12. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg. 2007;204:996–1005. [PubMed]
13. Kisfalvi K, Guha S, Rozengurt E. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J Cell Physiol. 2005;202:880–90. [PubMed]
14. Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res. 2005;65:2738–45. [PubMed]
15. Bierkamp C, Bonhoure S, Mathieu A, et al. Expression of cholecystokinin-2/gastrin receptor in the murine pancreas modulates cell adhesion and cell differentiation in vivo. Am J Pathol. 2004;165:2135–45. [PMC free article] [PubMed]
16. Rozengurt E, Rey O, Waldron RT. Protein Kinase D Signaling. J Biol Chem. 2005;280:13205–8. [PubMed]
17. Sinnett-Smith J, Zhukova E, Hsieh N, Jiang X, Rozengurt E. Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in swiss 3T3 cells. J Biol Chem. 2004;279:16883–93. [PubMed]
18. Sinnett-Smith J, Jacamo R, Kui R, et al. Protein Kinase D Mediates Mitogenic Signaling by Gq-coupled Receptors through Protein Kinase C-independent Regulation of Activation Loop Ser744 and Ser748 Phosphorylation. J Biol Chem. 2009;284:13434–45. [PMC free article] [PubMed]
19. Yuan J, Rozengurt E. PKD, PKD2, and p38 MAPK mediate Hsp27 serine-82 phosphorylation induced by neurotensin in pancreatic cancer PANC-1 cells. J Cell Biochem. 2008;103:648–62. [PubMed]
20. Trauzold A, Schmiedel S, Sipos B, et al. PKCmu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells. Oncogene. 2003;22:8939–47. [PubMed]
21. Kisfalvi K, Hurd C, Guha S, Rozengurt E. Induced overexpression of protein kinase D1 stimulates mitogenic signaling in human pancreatic carcinoma PANC-1 cells. J Cell Physiol. 2010 (in press) [PMC free article] [PubMed]
22. Santiskulvong C, Rozengurt E. Protein kinase Calpha mediates feedback inhibition of EGF receptor transactivation induced by G(q)-coupled receptor agonists. Cell Signal. 2007;19:1348–57. [PubMed]
23. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol. 2002;12:65–71. [PubMed]
24. Pawson T. Specificity in signal transduction: from phosphotyrosine-SH2 domain interactions to complex cellular systems. Cell. 2004;116:191–203. [PubMed]
25. Um SH, D’Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006;3:393–402. [PubMed]
26. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96. [PubMed]
27. Nakamura K, Sasajima J, Mizukami Y, et al. Hedgehog Promotes Neovascularization in Pancreatic Cancers by Regulating Ang-1 and IGF-1 Expression in Bone-Marrow Derived Pro-Angiogenic Cells. PLoS ONE. 5:e8824. [PMC free article] [PubMed]
28. Kornmann M, Maruyama H, Bergmann U, et al. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res. 1998;58:4250–4. [PubMed]
29. Kolb S, Fritsch R, Saur D, Reichert M, Schmid RM, Schneider G. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Res. 2007;67:4679–86. [PubMed]
30. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SA. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005;65:9164–8. [PubMed]
31. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun. 2005;331:295–302. [PubMed]
32. Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Curr Opin Cell Biol. 2009;21:199–208. [PMC free article] [PubMed]
33. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 27:5497–5510. [PMC free article] [PubMed]
34. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17:596–603. [PubMed]
35. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84. [PubMed]
36. Armengol G, Rojo F, Castellvi J, et al. 4E-binding protein 1: a key molecular “funnel factor" in human cancer with clinical implications. Cancer Res. 2007;67:7551–5. [PubMed]
37. Inoki K, Guan KL. Complexity of the TOR signaling network. Trends Cell Biol. 2006;16:206–12. [PubMed]
38. Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003;11:1457–66. [PubMed]
39. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5:578–81. [PubMed]
40. Sun Y, Fang Y, Yoon MS, et al. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A. 2008;105:8286–91. [PMC free article] [PubMed]
41. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953–70. [PubMed]
42. Gupta S, Ramjaun AR, Haiko P, et al. Binding of Ras to Phosphoinositide 3-Kinase p110[alpha] Is Required for Ras-Driven Tumorigenesis in Mice. Cell. 2007;129:957–68. [PubMed]
43. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642–6. [PMC free article] [PubMed]
44. Hardie DG. AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol. 2007;47:185–210. [PubMed]
45. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15–25. [PubMed]
46. Hezel AF, Bardeesy N. LKB1; linking cell structure and tumor suppression. Oncogene. 27:6908–19. [PubMed]
47. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–90. [PubMed]
48. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–9. [PubMed]
49. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126:955–68. [PubMed]
50. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint. Mol Cell. 2008;30:214–26. [PMC free article] [PubMed]
51. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001;120:1263–70. [PubMed]
52. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–73. [PubMed]
53. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin Inhibits Mammalian Target of Rapamycin Dependent Translation Initiation in Breast Cancer Cells. Cancer Res. 2007;67:10804–12. [PubMed]
54. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007;67:6745–52. [PubMed]
55. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission. Cancer Res. 2009;69:7507–11. [PMC free article] [PubMed]
56. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007;132:2208–25. [PubMed]
57. Nyman LR, Wells KS, Head WS, et al. Real-time, multidimensional in vivo imaging used to investigate blood flow in mouse pancreatic islets. J Clin Invest. 2008;118:3790–7. [PMC free article] [PubMed]
58. Chong CR, Chabner BA. Mysterious Metformin. Oncologist. 2009;14:1178–81. [PubMed]
59. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New Users of Metformin Are at Low Risk of Incident Cancer. Diabetes Care. 2009;32:1620–25. [PMC free article] [PubMed]
60. Li D, Yeung S-CJ, Hassan MM, Konopleva M, Abbruzzese JL. Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009;137:482–88. [PMC free article] [PubMed]

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...